

# **Benchmark Rates Liquidity Monitor**

#### OCTOBER 2021 | ISSUE 9

EONIA to ESTR conversion has been completed at CCPs in mid-October. This event moves the entire liquidity spectrum from EONIA to ESTR swaps now. GBP LIBOR swaps trading volumes continue to fall; however, some activity still remains ahead of GBP LIBOR cessation. SOFR trading continues to rise at an accelerated pace, although still remains below USD LIBOR trading activity levels. JPY TONA has now completely overtaken JPY LIBOR volumes.

#### **EUR**

ESTR monthly trading volumes in October reached 500bln. (**Chart 1**) according to the Swapsinfo data. The spike follows mid-October conversion at CCPs for all EONIA swaps to ESTR. Consequentially, monthly trade count moved jumped to 1,700 compared 200 to 400 in the previous months (**Chart 2**). EONIA and ESTR to EURIBOR trading ratios remain consistent in 5Y+ tenors, but have picked up at the short-end of the curve (**Charts 9 and 10**). From this edition onwards, we will no longer provide the EONIA to ESTR liquidity comparison, given that the CCPs have now converted all existing EONIA swaps to ESTR.

#### **GBP**

The transition from GBP LIBOR to SONIA in the GBP continues to progress, but the GBP LIBOR market still remains active. According to the Swapsinfo data GBP LIBOR trade count in October increased to 6,000 versus 12,000 in SONIA (**Chart 4**). Monthly trading volumes, however, are now entirely concentrated in SONIA swaps (4,500bln USD) rather than in GBP LIBOR (less than 500bln USD, **Charts 3 and 11**).

## **USD**


The impact from the SOFR First initiative continued to play out through October. Both SOFR trade volume and trade count reached all-time highs in October with SOFR volumes increasing 21% and count increasing 13.5% over September (**Charts 5 and 6**). The ratio of OIS to USD LIBOR monthly volumes for all maturities trended higher (**Charts 13 and 14**).

# **JPY**


In October, the trading volume for JPY TONA swap has continued its upward trend, increasing from 96 Billion to 126 Billion USD. On the contrary, trading volume for JPY LIBOR has shrunk by 50% to 51 Billion USD. Both types of swaps have increased in terms of trade count over the month (**Charts 7 and 8**). Looking at the tenor breakdowns (**Chart 15**), JPY OIS -to-LIBOR monthly volume ratio has increased consistently across all tenors, with all ratios hovering over 300%. There was also a much higher number of JPY OIS swap trades done in the 0-2y part of the curve relative to the number of JPY LIBOR type trades in the same tenor (approximately 2 times higher).

#### IRS AND OIS TOTAL LIQUIDITY


#### 1: EURIBOR AND ESTR MONTHLY TRADING VOLUME (USD BLN)




#### 2: EURIBOR AND ESTR MONTHLY TRADE COUNT



#### 3: GBP LIBOR AND SONIA MONTHLY TRADING VOLUME (USD BLN)




#### 4: GBP LIBOR AND SONIA MONTHLY TRADE COUNT




## 5: USD LIBOR AND SOFR MONTHLY TRADING VOLUME (USD BLN)




#### 6: USD LIBOR AND SOFR MONTHLY TRADE COUNT



## 7: JPY LIBOR AND TONA MONTHLY TRADING VOLUME (USD BLN)




## 8: JPY LIBOR AND TONA MONTHLY TRADE COUNT




#### IRS AND OIS LIQUIDITY PER TENOR


#### 9: ESTR AND EONIA OIS TO EURIBOR IRS MONTHLY VOLUME RATIO




## 10: ESTR AND EONIA OIS TO EURIBOR IRS MONTHLY TRADE COUNT RATIO




#### 11: SONIA OIS TO GBP LIBOR IRS MONTHLY VOLUME RATIO




12: SONIA OIS TO GBP LIBOR IRS MONTHLY TRADE COUNT RATIO




### 13: OIS TO USD LIBOR IRS MONTHLY VOLUME RATIO




14: OIS TO USD LIBOR IRS MONTHLY TRADE COUNT RATIO



## 15: OIS TO JPY LIBOR IRS MONTHLY VOLUME RATIO




#### 16: OIS TO JPY LIBOR IRS MONTHLY TRADE COUNT RATIO




# **USD OIS LIQUIDITY - OCTOBER 2021**

# 17: FED FUNDS VS SOFR TRADE VOLUME PER TENOR (USD BLN)



## 18: FED FUNDS VS SOFR TRADE COUNT PER TENOR



#### MILLIMAN BENCHMARK RATES LIQUIDITY MONITOR

#### Disclaimers

Milliman Financial Strategies ("Milliman") has compiled the information in this document with care. This information is only intended for eligible counterparties and/or professional investors as referred to in the Financial Supervision Act ("Wft").

This document does not contain (i) an offer of invitation to buy, sell or trade financial instruments (within the meaning of 1: 1 Wft), (ii) no investment recommendation or investment advice (within the meaning of 1: 1 Wft), and (iii) no legal or tax advice. Consult a legal or tax advisor. Milliman recommends that you not to base any investment or other decision solely on the information contained in this document. Milliman is not liable for damage resulting from such an (investment) decision.

The information in this document is (partly) based on information obtained by Milliman from sources believed to be reliable. Milliman does not warrant the reliability of those sources or the accuracy and completeness of the information obtained from those sources. The information in this document is purely informative and you cannot derive any rights from it. All information is a snapshot, unless expressly stated otherwise. The information is not representative of the views of Milliman or its parent companies, subsidiaries or affiliates. Distribution of this document after the original publication date is no guarantee that the information contained herein is still accurate and complete at that later date. Milliman reserves the right to change this information without notice. The used returns on investments in this document is for the purpose of explanation and explanation only. Milliman does not express any expectations about the return or price development of those investments. The value of your investment may fluctuate and past performance is no guarantee for the future. The information in this document is based on assumptions made by Milliman. Assumptions other than those made by Milliman may be made. The conclusions drawn by Milliman are therefore not necessarily correct and / or complete.

You may copy the information in this document for your own personal use only. You may not copy, reproduce, distribute, or disclose the information without Milliman's written consent. All information (texts, photos, illustrations, graphics, trade names, logos, and marks) remains the property of or licensed to Milliman and is protected by copyright, trademark and / or intellectual property law. No rights or licenses are transferred when using or accessing this information.

Issued by: Milliman Financial Strategies B.V., with its registered office and office in Amsterdam. Milliman is registered with the Netherlands Authority for the Financial Markets ("AFM") in Amsterdam as an investment firm as referred to in Section 2:96 Wft and is authorized under this license to provide investment services as included in the register kept by the AFM.



Milliman is among the world's largest providers of actuarial and related products and services. The firm has consulting practices in life insurance and financial services, property & casualty insurance, healthcare, and employee benefits. Founded in 1947, Milliman is an independent firm with offices in major cities around the globe.

milliman.com

For more information, please contact your Milliman consultant.

© 2021 Milliman, Inc. All Rights Reserved. The materials in this document represent the opinion of the authors and are not representative of the views of Milliman, Inc. Milliman does not certify the information, nor does it guarantee the accuracy and completeness of such information. Use of such information is voluntary and should not be relied upon unless an independent review of its accuracy and completeness has been performed. Materials may not be reproduced without the express consent of Milliman.